{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:24Z","timestamp":1791924204053,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.ajkd.2026.04.012","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:08:39Z","timestamp":1782850119000},"page":"485-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kidney Transplantation Post\u2013Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma"],"prefix":"10.1053","volume":"88","author":[{"given":"Zahraa","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshana M.","family":"Dadhania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Brailovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1053\/j.ajkd.2026.04.012_bib1","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.012_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study","volume":"25","author":"Tsakiris","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.012_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ckj\/sfy137","article-title":"Risk of relapse of multiple myeloma following kidney transplantation","volume":"12","author":"Shah","year":"2019","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1053\/j.ajkd.2026.04.012_bib4","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2026.04.012_bib5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/ndt\/gfac196","article-title":"Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA","volume":"37","author":"Ng","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2026.04.012_bib6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.012_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2026.04.012_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.012_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2026.04.012_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2026.04.012_bib11","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1053\/j.ajkd.2026.04.012_bib12","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2026.04.012_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100856","article-title":"Chimeric antigen receptor (CAR) t-cell therapy use in patients with multiple myeloma and kidney failure on maintenance hemodialysis: a report of 2 cases","volume":"6","author":"Pak","year":"2024","journal-title":"Kidney Med"},{"issue":"5","key":"10.1053\/j.ajkd.2026.04.012_bib14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00277-023-05163-z","article-title":"Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis","volume":"102","author":"W\u00e4sch","year":"2023","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.04.012_bib15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2016.11.024","article-title":"Acute kidney allograft rejection precipitated by lenalidomide treatment for multiple myeloma","volume":"69","author":"Lum","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.012_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/bmt.2008.320","article-title":"Acute cellular rejection in a renal allograft immediately following leukocyte engraftment after auto-SCT","volume":"43","author":"Leung","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1053\/j.ajkd.2026.04.012_bib17","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.ajkd.2026.04.012_bib18","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1053\/j.ajkd.2026.04.012_bib19","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.04.012_bib20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.kint.2025.07.011","article-title":"Management recommendations for kidney transplantation in patients with plasma cell dyscrasia","volume":"108","author":"Murakami","year":"2025","journal-title":"Kidney Int"},{"issue":"23","key":"10.1053\/j.ajkd.2026.04.012_bib21","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"10.1053\/j.ajkd.2026.04.012_bib22","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.ajkd.2026.04.012_bib23","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1200\/OP-24-00752","article-title":"Novel treatment options for multiple myeloma","volume":"21","author":"Portuguese","year":"2025","journal-title":"JCO Oncol Pract"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626009844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626009844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:41:53Z","timestamp":1787215313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626009844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0272638626009844"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.04.012","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney Transplantation Post\u2013Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}